Alpharmaxim helps organisations close the gap between ambition and the real‑world adoption of change. Across biopharma, teams invest heavily in strong strategies and well‑executed plans — yet adoption often falls short. The challenge today is rarely a lack of effort or intent. It is having confidence that decisions, investment and communications will genuinely change behaviour in the real world. We are specialists in the practical application of behavioural science, working with organisations to design strategies and communications that change behaviour — and make adoption stick. Our approach embeds behavioural science into how decisions are made, not added on afterwards. By identifying the beliefs and barriers that shape real‑world behaviour, we help teams bridge strategy and execution, align around shared behavioural goals, and move beyond activity metrics to evidence of meaningful change. Using proprietary behavioural frameworks, published research and deep sector expertise, we support medical, commercial and corporate teams to justify strategic choices, align stakeholders and increase the likelihood that change is adopted — whether that is a therapy reaching patients, a strategic shift landing internally, or new ways of working taking hold. From well‑executed plans to well‑executed change! To get into conversation with us - please follow and subscribe to our newsletter
Looking for a particular Alpharmaxim employee's phone or email?
The Alpharmaxim annual revenue was $5.5 million in 2026.
William Hind is the CEO of Alpharmaxim.
26 people are employed at Alpharmaxim.
The NAICS codes for Alpharmaxim are [541810, 5418, 54, 541, 54181].
The SIC codes for Alpharmaxim are [73, 731].